Stephens & Co. Maintains Overweight on Repligen, Raises Price Target to $200
Portfolio Pulse from richadhand@benzinga.com
Stephens & Co. analyst Jacob Johnson maintains an Overweight rating on Repligen (NASDAQ:RGEN) and raises the price target from $180 to $200.
August 04, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repligen's price target has been raised from $180 to $200 by Stephens & Co. The firm maintains an Overweight rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase. The Overweight rating suggests that the analyst believes the stock will outperform the market in the future. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100